title: Economic burden of periprosthetic joint infection in the United States.
abstract: This study characterizes the patient and clinical factors influencing the economic burden of periprosthetic joint infection (PJI) in the United States. The 2001-2009 Nationwide Inpatient Sample was used to identify total hip and knee arthroplasties using International Classification of Diseases, Ninth Revision, procedure codes. The relative incidence of PJI ranged between 2.0% and 2.4% of total hip arthroplasties and total knee arthroplasties and increased over time. The mean cost to treat hip PJIs was $5965 greater than the mean cost for knee PJIs. The annual cost of infected revisions to US hospitals increased from $320 million to $566 million during the study period and was projected to exceed $1.62 billion by 2020. As the demand for joint arthroplasty is expected to increase substantially over the coming decade, so too will the economic burden of prosthetic infections.
authors.affiliation: Exponent, Inc, Philadelphia, Pennsylvania; Drexel University, Philadelphia, Pennsylvania, USA.
authors.forename: Steven M
authors.initials: SM
authors.lastname: Kurtz
authors.forename: Edmund
authors.initials: E
authors.lastname: Lau
authors.forename: Heather
authors.initials: H
authors.lastname: Watson
authors.forename: Jordana K
authors.initials: JK
authors.lastname: Schmier
authors.forename: Javad
authors.initials: J
authors.lastname: Parvizi
mesh_terms: D017048:Health Care Costs; D006622:Hip Prosthesis / Q000009:adverse effects*; D006801:Humans; D007720:Knee Prosthesis / Q000009:adverse effects*; D016459:Prosthesis-Related Infections / Q000191:economics* / Q000453:epidemiology / Q000209:etiology*; D013997:Time Factors; D014481:United States / Q000453:epidemiology